The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Abstract
A total of 378 novel drugs and 27 biosimilars approved by the U.S. Food and Drug Administration (FDA) between 2010 and 2019 were evaluated according to approval numbers by year, therapeutic areas, modalities, route of administration, first-in-class designation, approval times, and expedited review categories. From this review, oncology remains the top therapy area (25%), followed by infection (15%) and central nervous system disorders (11%). Regulatory incentives have been effective as evidenced by an increase in orphan drugs as well as antibacterial drugs approved under the GAIN act. Clinical development times may be increasing, perhaps as a result of the increase in orphan drug indications. Small molecules continue to mostly adhere to "Rule of 5" (Ro5) parameters, but innovation in new modalities is rapidly progressing with approvals for antisense oligonucleotides (ASO), small-interfering RNA (siRNAs), and antibody-directed conjugates (ADCs). Finally, novel targets and scientific breakthroughs that address areas of unmet clinical need are discussed in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Sulkowski, M. S., Gardiner, D. F., Rodriguez-Torres, M., Reddy, K. R., Hassanein, T., Jacobson, I., Lawitz, E., Lok, A. S., Hinestrosa, F., Thuluvath, P. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306218 · Cited by 1,190
LAG 3 (CD 223) as a cancer immunotherapy target
Andrews, L. P., Marciscano, A. E., Drake, C. G., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 956
Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30115-1 · Cited by 935
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
Self-citationFDA-Approved Oligonucleotide Therapies in 2017
Stein, C. A., & Castanotto, D. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.023 · Cited by 608
Kolb, S. J., & Kissel, J. T. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.004 · Cited by 603
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Burosumab Therapy in Children with X-Linked Hypophosphatemia
Carpenter, T. O., Whyte, M. P., Imel, E. A., Boot, A. M., Högler, W., Linglart, A., Padidela, R., van’t Hoff, W., Mao, M., Chen, C.-Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714641 · Cited by 479
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
Morgan, P., Brown, D. G., Lennard, S., Anderton, M. J., Barrett, J. C., Eriksson, U., Fidock, M., Hamrén, B., Johnson, A., March, R. E., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.244 · Cited by 452
Self-citationShultz, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00686 · Cited by 434
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 429
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01269-0 · Cited by 420
Lee, J. W., Sicre de Fontbrune, F., Wong Lee Lee, L., Pessoa, V., Gualandro, S., Füreder, W., Ptushkin, V., Rottinghaus, S. T., Volles, L., Shafner, L., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876136 · Cited by 416
The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
FDA Approval and Regulation of Pharmaceuticals, 1983-2018
Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2020) · JAMA · doi:10.1001/jama.2019.20288 · Cited by 377
Critical analysis of antibacterial agents in clinical development
Theuretzbacher, U., Bush, K., Harbarth, S., Paul, M., Rex, J. H., Tacconelli, E., & Thwaites, G. E. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0340-0 · Cited by 373
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
Shirley, M. (2018) · Drugs · doi:10.1007/s40265-018-0902-x · Cited by 371
Thorsell, A.-G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., Moche, M., Cohen, M. S., & Schüler, H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00990 · Cited by 358
Goldner, T., Hewlett, G., Ettischer, N., Ruebsamen‐Schaeff, H., Zimmermann, H., & Lischka, P. (2011) · Journal of Virology · doi:10.1128/jvi.05265-11 · Cited by 336
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Fok, J. H. L., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12836-9 · Cited by 331
Lecona, E., & Fernandez-Capetillo, O. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 325
Osimertinib: First Global Approval
Greig, S. L. (2016) · Drugs · doi:10.1007/s40265-015-0533-4 · Cited by 322
Heo, Y.-A. (2020) · Drugs · doi:10.1007/s40265-020-01267-2 · Cited by 317
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
A resurrection of aducanumab for Alzheimer's disease
Schneider, L. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30480-6 · Cited by 286
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea
Taylor, S. N., Marrazzo, J., Batteiger, B. E., Hook, E. W., Seña, A. C., Long, J., Wierzbicki, M. R., Kwak, H., Johnson, S. M., Lawrence, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706988 · Cited by 243
Jin, M. H., & Oh, D.-Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.002 · Cited by 239
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Emu, B., Fessel, J., Schrader, S., Kumar, P., Richmond, G., Win, S., Weinheimer, S., Marsolais, C., & Lewis, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711460 · Cited by 227
Konstantinopoulos, P. A., Cheng, S.-C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 225
Edaravone: A new drug approved for ALS
Rothstein, J. D. (2017) · Cell · doi:10.1016/j.cell.2017.10.011 · Cited by 219
Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01207-9 · Cited by 205
Neurodegenerative disease: Brain windfall
Gammon, K. (2014) · Nature · doi:10.1038/nj7526-299a · Cited by 200
Gene editing and CRISPR in the clinic: current and future perspectives
Hirakawa, M. P., Krishnakumar, R., Timlin, J. A., Carney, J. P., & Butler, K. S. (2020) · Bioscience Reports · doi:10.1042/bsr20200127 · Cited by 192
Kesselheim, A. S., Wang, B., Franklin, J. M., & Darrow, J. J. (2015) · BMJ · doi:10.1136/bmj.h4633 · Cited by 189
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 189
Phyo, A. P., Jittamala, P., Nosten, F. H., Pukrittayakamee, S., Imwong, M., White, N. J., Duparc, S., Macintyre, F., Baker, M., & Möhrle, J. J. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00320-5 · Cited by 185
Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy
Griggs, R. C., Miller, J. P., Greenberg, C. R., Fehlings, D. L., Pestronk, A., Mendell, J. R., Moxley, R. T., King, W., Kissel, J. T., Cwik, V., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003217 · Cited by 185
Pembrolizumab: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0314-5 · Cited by 184
Where Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Self-citationAtaxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
Mei, L., Zhang, J., He, K., & Zhang, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0733-6 · Cited by 163
Molecular Property Design: Does Everyone Get It?
Leeson, P. D., & Young, R. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00157 · Cited by 162
Evolving Role for Pharmacotherapy in NAFLD/NASH
Attia, S. L., Softic, S., & Mouzaki, M. (2020) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 142
Tinworth, C. P., & Young, R. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01596 · Cited by 140
COVID-19: A review of the proposed pharmacological treatments
Lam, S., Lombardi, A. M., & Ouanounou, A. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173451 · Cited by 135
Why Some Targets Benefit from beyond Rule of Five Drugs
Egbert, M. E., Whitty, A., Keserű, G. M., & Vajda, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01732 · Cited by 134
FDA adds "black box" warning label to fluoroquinolone antibiotics
Tanne, J. H. (2008) · BMJ · doi:10.1136/bmj.a816 · Cited by 133
Ridley, K., & Condren, M. E. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.3.192 · Cited by 131
NEW PERSPECTIVES ON THE BIOLOGY AND TREATMENT OF X-LINKED HYPOPHOSPHATEMIC RICKETS
Carpenter, T. O. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70485-5 · Cited by 129
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
Cottrell, T. R., & Taube, J. M. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000301 · Cited by 126
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 124
Scheerens, H., Malong, A., Bassett, K., Boyd, Z. S., Gupta, V., Harris, J. M., Mesick, C. P., Simnett, S., Stevens, H., Gilbert, H., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12455 · Cited by 121
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Young, R. J., & Leeson, P. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00180 · Cited by 120
Peck, M. C., Rothenberg, M. E., Deng, R., Lewin‐Koh, N., She, G., Kamath, A. V., Carrasco‐Triguero, M., Saad, O. M., Castro, A., Teufel, L. U., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02588-18 · Cited by 118
Infectious Complications Associated with Monoclonal Antibodies and Related Small Molecules
Salvaña, E. M. T., & Salata, R. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-08 · Cited by 116
Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria
White, N. J., Duong, T. T., Uthaisin, C., Nosten, F. H., Phyo, A. P., Hanboonkunupakarn, B., Pukrittayakamee, S., Jittamala, P., Chuthasmit, K., Cheung, M. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602250 · Cited by 114
Sofosbuvir: First Global Approval
Keating, G. M., & Vaidya, A. (2014) · Drugs · doi:10.1007/s40265-014-0179-7 · Cited by 112
CD19 as an attractive target for antibody-based therapy
Hammer, O. (2012) · mAbs · doi:10.4161/mabs.21338 · Cited by 102
Scott, L. J. (2020) · Drugs · doi:10.1007/s40265-020-01264-5 · Cited by 102
FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder
Joffe, H. V., Chang, C. Y., Sewell, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1513686 · Cited by 97
The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
Wobst, H. J., Mack, K. L., Brown, D. G., Brandon, N. J., & Shorter, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21661 · Cited by 97
Self-citationAntisense oligonucleotides for neurodegeneration
Leavitt, B. R., & Tabrizi, S. J. (2020) · Science · doi:10.1126/science.aba4624 · Cited by 96
The FDA’s Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016
Hwang, T. J., Darrow, J. J., & Kesselheim, A. S. (2017) · JAMA · doi:10.1001/jama.2017.14896 · Cited by 86
Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0381-2 · Cited by 80
COVID-19 Therapeutic Options Under Investigation
Kaddoura, M., Ibrahim, M. A., Hijazi, G., Soudani, N., Audi, A., Alkalamouni, H., Haddad, S., Eid, A. H., & Zaraket, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01196 · Cited by 80
Erenumab: First Global Approval
Markham, A. (2018) · Drugs · doi:10.1007/s40265-018-0944-0 · Cited by 77
The current development of CNS drug research
Wegener, G., & Rujescu, D. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000345 · Cited by 76
Galcanezumab: First Global Approval
Lamb, Y. N. (2018) · Drugs · doi:10.1007/s40265-018-1002-7 · Cited by 55
Are Development Times For Pharmaceuticals Increasing Or Decreasing?
Keyhani, S., Diener‐West, M., & Powe, N. R. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.461 · Cited by 54
Clinical trial cycle times continue to increase despite industry efforts
Martin, L., Hutchens, M., & Hawkins, C. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.21 · Cited by 53
Fremanezumab: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-1004-5 · Cited by 52
Howe, A., & Venkatraman, S. (2013) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2013.002xx · Cited by 48
Drug Development and FDA Approval, 1938–2013
Darrow, J. J., & Kesselheim, A. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402114 · Cited by 47
Opportunistic Infections in Biological Therapy, Risk and Prevention
Bryant, P. A., & Baddley, J. W. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.005 · Cited by 38
Why has R&D productivity declined in the pharmaceutical industry?
Ruffolo, R. R., Jr. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.2.99 · Cited by 37
Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal
Doughty, B. J., Morgenson, D., & Brooks, T. A. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019828954 · Cited by 37
The evolution of the regulatory framework for antibacterial agents
Rex, J. H., Goldberger, M. J., Eisenstein, B. I., & Harney, C. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12441 · Cited by 32
Strategies to Address Challenges in Neuroscience Drug Discovery and Development
O’Donnell, P., Rosen, L. B., Alexander, R., Murthy, N. V., Davies, C. H., & Ratti, E. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz027 · Cited by 31
Kang, D. W., Jadin, L., Nekoroski, T., Drake, F. H., & Zepeda, M. L. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0065-3 · Cited by 27
Expedited drug review process: Fast, but flawed
Chary, K. V. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.184768 · Cited by 21
Targeted degraders clear first safety hurdles
Mullard, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00109-w · Cited by 21
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imajo, K., Saito, S., & Nakajima, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543403 · Cited by 20
Therapeutic Antisense Targeting of Huntingtin
Smith, A. V., & Tabrizi, S. J. (2019) · DNA and Cell Biology · doi:10.1089/dna.2019.5188 · Cited by 17
Moxidectin for deworming: from trials to implementation
Maheu‐Giroux, M., & Joseph, S. A. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30270-6 · Cited by 9
FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults
Administration, U. S. F. &. D. (2018) · Case Medical Research · doi:10.31525/fda2-ucm607884.htm · Cited by 9
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Adel, A. (2022) · Journal of Cloud Computing · doi:10.1186/s13677-022-00314-5 · Cited by 864
The Expanding Role of Pyridine and Dihydropyridine Scaffolds in Drug Design
Ling, Y., Hao, Z.-Y., Liang, D., Zhang, C.-L., Liu, Y.-F., & Wang, Y. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s329547 · Cited by 414
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Metadata
- Authors
- Brown, D. G., & Wobst, H. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-02-22
- Volume
- 64
- Issue
- 5
- Pages
- 2312-2338
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3130309548
- Cited by
- 320
- References
- 116
- FWCI
- 38.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.